180 related articles for article (PubMed ID: 35756637)
1. H3K27M Mutation Doesn't Mean Worse Prognosis in Old Patients.
Hu XM; Nie XY; Xu KL; Wang Y; Tang F; Du ZG; Xiong J
Front Oncol; 2022; 12():912166. PubMed ID: 35756637
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
3. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
[TBL] [Abstract][Full Text] [Related]
7. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study.
Wang Y; Feng LL; Ji PG; Liu JH; Guo SC; Zhai YL; Sankey EW; Wang Y; Xue YR; Wang N; Lou M; Xu M; Chao M; Gao GD; Qu Y; Gong L; Wang L
Front Oncol; 2020; 10():602553. PubMed ID: 33659209
[TBL] [Abstract][Full Text] [Related]
9. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
[No Abstract] [Full Text] [Related]
11. Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation.
Hassan U; Latif M; Yousaf I; Bin Anees S; Mushtaq S; Akhtar N; Loya A
Cureus; 2021 Aug; 13(8):e17267. PubMed ID: 34540489
[TBL] [Abstract][Full Text] [Related]
12. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
[No Abstract] [Full Text] [Related]
13. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
[TBL] [Abstract][Full Text] [Related]
14. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
15. H3K27M and
Osada Y; Saito R; Shibahara I; Sasaki K; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
Neurooncol Adv; 2021; 3(1):vdab038. PubMed ID: 34013205
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy in H3K27M diffuse midline glioma.
Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Findings of Thalamic and Brainstem Glioma Including Diffuse Midline Glioma, H3K27M Mutant:A Clinical Study].
Kim Y; Kudo T; Tamura K; Sumita K; Kobayashi D; Tanaka Y; Inaji M; Nariai T; Ishii K; Maehara T
No Shinkei Geka; 2021 Jul; 49(4):901-908. PubMed ID: 34376622
[TBL] [Abstract][Full Text] [Related]
19. Diffuse midline glioma H3K27M mutation in adult: A case report.
Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
[TBL] [Abstract][Full Text] [Related]
20. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]